Navigation Links
Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development
Date:3/11/2008

STRASBOURG, France, March 11 /PRNewswire-FirstCall/ -- Transgene (Euronext Paris: FR0005175080) announces today its achievements in operations, financial performance for 2007 and outlook for 2008.

"2007 was a breakthrough year for Transgene, marked by two major accomplishments: the signing of a partnership agreement with Roche in the domain of therapeutic vaccines for the treatment of diseases caused by the HPV virus, and the successful completion of a EUR100.1m capital increase on European markets," declared Philippe Archinard, Managing Director of Transgene.

Key financial highlights include:

- Total revenues for the year were EUR28million compared to EUR5.5m in 2006.

- Transgene closed the year with a net loss of EUR5.5m compared to a net loss of EUR22m a year earlier.

- Basic loss per ordinary share was EUR0.28 versus EUR1.41 in 2006.

- Research and development expenditures were EUR28.8m compared to EUR24.2m in 2006.

- In 2007, net cash expenditure, excluding capital increase, was EUR5.5m compared to EUR20.7m in 2006.

- At the end of 2007, the company held cash and cash equivalents of EUR111.3m, which should enable it to finance some four years of operating costs.

Major Accomplishments of 2007:

Partnership Roche /Transgene: announced in April 2007, an exclusive world wide license agreement aimed at the development, registration and commercialisation of Transgene's therapeutic vaccines developed to fight diseases caused by the Human Papilloma Virus. Transgene received an upfront payment and a regulatory milestone of EUR23m in June 2007 and may receive further payments of up to EUR195m covering clinical development milestones and commercial milestones based on future sales of HPV products, stemming from Transgene's research. Under the terms of the agreement, Transgene is also entitled to receive progressive, double digit royalties on all future sales.

Strengthening of the Equity Bas
'/>"/>

SOURCE Transgene S.A.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
2. Transgene: Cash Position of EUR 119 Million as of September 30, 2007
3. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
4. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
5. Medline and 3M Agree to Strategic Partnership in Electrosurgery
6. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
7. B-Line Medical and Immersion Medical Announce Partnership
8. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
9. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
10. ExonHit and bioMerieux Amend Their Strategic Partnership
11. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2008)...Symbol: MS, EDMONTON, Oct. 3 /PRNewswire-FirstCal...loper in the treatment of multiple sclerosis (MS),...Monitoring Board (DSMB) for the,Company,s U.S. piv...8298),in patients with secondary progressive MS ha... the trial continue as per the protocol., This wa...
(Date:10/3/2008)...or Ap3ana, CTI,s ,personalized medicine, venture, ...erapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ...t recently President and COO of a Tyr Pharma and f...mics Institute of the Novartis Research,Foundation... Bresso, Italy,CTI Europe currently conducts the ...
(Date:10/2/2008)...2 /- Helix BioPharma,Corp. ... its private,placement announced on September 30, ...ss proceeds totaling CDN$11,424,000., Each unit c...mmon share,purchase warrant, with each whole commo...urchase, subject to adjustment, one common share a...
(Date:10/2/2008)...Provides Business Update to Investors, WILMINGTON...today at an,investor conference, DuPont Vice Presi...ny,s plans to bring its two advanced biofuels prog... technical progress toward the,commercialization o...stocks,economically into biofuels., "Biobutanol a...
Breaking Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
...ggests Wisconsin is slowly making progress when it...judged by indicators such as producing patents, in...reating high-tech jobs. The natural question: Why ...ut a variety of factors promise more progress pro...ion. , ,The report, commissioned by the Wisconsin...
...olumn over the last few years knows about my prope...e information into tidy boxes in some meaningful o...out of the information for myself). While my list ...ow enlightened me about how lists could be used to...n one of my companies, I even adapted the Letterma...
...y to pick up a pizza the other night. I ran into ...rbis, the massive digital image library. Doug is...g product for digital pictures. , ,If, like me, yo...red on your mobile phone the moment for sharing ha...package provides everything you need to create a t...
...chnology-wise has already been invented. I,ve been...last 15 years about technology innovation, and the... all that innovation. From a quick look into the i...ular soapbox is getting crowded. Pick up any indus...ons about process, best practices, business alignm...
Other Biology Technology:Heres why Wisconsins tech economy indicators are up 2Heres why Wisconsins tech economy indicators are up 3Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says 2Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says 3Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says 4ZoomAlbum operates virtually 2ZoomAlbum operates virtually 3The end of technology history 2The end of technology history 3
(Date:10/6/2008)...722; The American Physiological Society has establ...estricted grants of up to $2,000 to support physio...o suffered losses as a result of Hurricane Ike. Th...nd also affected other areas of the country. , T... are either APS members or working in the laborato...
(Date:10/5/2008)...rnal of Cell Biology how the altered behavior of ...cells., On 2D surfaces, cells may migrate randoml... link the cell to the extracellular matrix, are kn...y how has been unclear. Recent work has suggested ...t, while an integrin called avb3 has been associat...
(Date:10/5/2008)...sts report online this week in Nature that they ...ells to a gene associated with Crohn,s disease, an...lammatory bowel disorder. , The link to immune c...y School of Medicine in St. Louis because they and...rected immune responses in the intestine that dama...
(Date:10/3/2008)...008)Researchers from Harvard Medical School and th...how beetles and bacteria form a symbiotic and mutu... the destruction of pine forests. In addition, the...this whole phenomenon. , The context of this di... includes some of the most unlikely characters and...
Breaking Biology News(10 mins):Form of Crohn's disease traced to disabled gut cells 2Cross kingdom conflicts on a beetle's back 2Cross kingdom conflicts on a beetle's back 3Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore 517 1Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore 517 2Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 1Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 2Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 3Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 4Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 5Nyer Medical Group Inc Reports EPS of 24 02 on Record Revenues of 2469 9 Million for Fiscal Year Ended 2007 3692 1Nyer Medical Group Inc Reports EPS of 24 02 on Record Revenues of 2469 9 Million for Fiscal Year Ended 2007 3692 2Nyer Medical Group Inc Reports EPS of 24 02 on Record Revenues of 2469 9 Million for Fiscal Year Ended 2007 3692 3Nyer Medical Group Inc Reports EPS of 24 02 on Record Revenues of 2469 9 Million for Fiscal Year Ended 2007 3692 4Americas Top Hospitals Are Real Lifesavers 3690 1Americas Top Hospitals Are Real Lifesavers 3690 2
...have discovered a vast network of neurons in the b...s the effects of reproductive status on other brai...ound neural circuits that coordinate a complex int...nd brain areas that carry the neural signals trigg...heromones, chemical signals produced by animals. T...
...ntified two new genes that operate as regulators i...ococcus aureus , one of the bacteria most frequent...ts, and has explained the functioning of a structu... was the subject of a PhD thesis recently defended...IC and Public University of Navarra centre, and is...
...ngi, such as white rot, are particularly harmful f... Soil samples are investigated to detect this; a l...with the Laboratory for Nematology (University of ...ular technique to detect the stem nematode and whi... Blgg will start using the new system in November ...
...herapy (HAART) for HIV infection remain susceptibl...or HIV-infected patients not on HAART, according t...ctious Diseases, now available online. , Opportun...fatal for immunocompromised patients. HAART not on...n helps to keep other infections such as TB under ...
Other Biology News:The brain is broadly wired for reproduction 2The brain is broadly wired for reproduction 3The brain is broadly wired for reproduction 4The brain is broadly wired for reproduction 5Genes involved in biofilms 2DNA technique measures suitability of soil for onion crops 2Tuberculosis still a risk for patients receiving HIV drugs 2
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum.
...EnzChek Pyrophosphate Detection Kit,provides a fas...ethod for measuring the inorganic pyrophosphate (P..., such as DNA and,RNA polymerizations, cyclic AMP ...enzymatic activation of fatty acids to,form their ...
...ose Gel-Digesting Preparation contains a unique &b...RE for simple, quantitative recovery of intact DNA... following electrophoresis in TAE, TBE, MOPS, or p... in the TAE, TBE, MOPS, and phosphate electrophore...
Request Info
Biology Products: